Skip to main content

Table 1 A summary of Thimerosal-containing DTaP vaccine administration in comparison to Thimerosal-free DTaP vaccine as a risk factor for ASD adverse event reports in the VAERS

From: A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States

Group examined Number autism/Autism spectrum disorder events Net number of doses distributed (1998–2000) Risk ratio (95% CI) p-value
Thimerosal-Containing DTaP Vaccine 38 16,335,650   
    2.02 (1.15–3.56) < 0.02
Thimerosal-Free DTaP Vaccine 17 14,794,210